Home » Bioenvision Provides Evoltra Regulatory Update
Bioenvision Provides Evoltra Regulatory Update
Bioenvision announced an update on the status of its Marketing Authorization Application to the European Medicines Evaluation Agency (EMEA) to include a new indication for Evoltra (clofarabine) for the treatment of acute myeloid leukemia (AML) in elderly patients who have one or more of the following: adverse cytogenetics, secondary AML, ≥ 70 years old or significant co-morbidities and are therefore not considered suitable for intensive chemotherapy.
Bioenvision
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May